ClinicalTrials.gg
RecruitingNCT04445571SAINTUpdated Jul 1, 2025

Surfactant Administration by Insure or Thin Catheter

An interventional study of Thin catheter technique or standard ET-tube for surfactant administration in RDS of Prematurity, Surfactant Deficiency Syndrome Neonatal and Analgesia, sponsored by Karolinska Institutet. Recruiting at 1 site in Sweden. Open to participants aged Up to 2 Days. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
Up to 2 Days
Sex
All
01

Study summary

This trial evaluates the efficacy and safety of surfactant administration with thin catheter technique together with analgesic premedication in comparison with the established INSURE-strategy. It will provide valuable knowledge to improve clinical methodology and enhance lung protective treatment strategies for preterm infants.

Read the detailed description

To compare two approaches for surfactant administration during CPAP in preterm infants, the INSURE and the LISA technique, using premedication intubation protocols, and investigate aspects of safety, stress and pain, timely administration of the drug, response in oxygenation and pulmonary outcome.

Our study asks whether (P) among infants born \<32 weeks' gestation with RDS (I) does surfactant administration with LISA and analgesia premedication (C) versus surfactant administration according to the INSURE protocol (O) improve oxygenation and reduce the rate of respiratory failure and need for intubation and mechanical ventilation (T) within 48 hours of the procedure

Primary outcomes:

  1. Positive effect: Oxygenation measured as arterial to alveolar ratio (a/A ratio) at 24 hours post-procedure.
  2. Negative effect: Need for mechanical ventilation (MV) within 48 hours post-procedure.

Safety outcomes:

  1. Time from meeting the FiO2 or a/A ratio criteria for surfactant treatment until surfactant administration
  2. Number of tries before successful intubation/placement of catheter
  3. Positive pressure ventilation during the procedure - yes/no/duration (minutes)
  4. Stress and pain (changes in heart rate, blood pressure and BIIP-scale)
02

Conditions studied

  • RDS of Prematurity
  • Surfactant Deficiency Syndrome Neonatal
  • Analgesia

Keywords

  • LISA (Less invasive surfactant administration)
  • INSURE
  • CPAP
03

In context

Respiratory Distress Syndrome In Premature Infants

34 studies on the registry are indexed under Respiratory Distress Syndrome In Premature Infants; 10 are open to participants now.

This study's planned enrollment of 160 is above the median of 45 across 29 interventional studies indexed under Respiratory Distress Syndrome In Premature Infants.

Browse Respiratory Distress Syndrome In Premature Infants studies →

Lead sponsor

Karolinska Institutet is the lead sponsor of 1,150 studies on the registry; 276 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 2 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants born before 32 completed weeks of gestation on CPAP, with clinical and radiological signs of RDS and need for surfactant treatment.

Exclusion criteria

Exclusion Criteria:

  • Infants requiring surfactant as part of delivery room resuscitation are not eligible.

Infants will be excluded from the final analysis if they have a congenital abnormality or condition that might have an adverse effect on breathing or ventilation, including: congenital diaphragmatic hernia; tracheo-oesophageal fistula or cyanotic heart disease.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Active comparator
    INSURE

    Surfactant administration by Intubation-surfactant-extubation to CPAP according to standard protocol including premedication with analgesia and sedation.

    Procedure: Thin catheter technique or standard ET-tube for surfactant administration

  • Active comparator
    LISA

    Surfactant administration by thin catheter during spontaneous breathing and continued CPAP according to set protocol including premedication with analgesia.

    Procedure: Thin catheter technique or standard ET-tube for surfactant administration

Interventions

  • ProcedureThin catheter technique or standard ET-tube for surfactant administration

    Surfactant administration by intubation with regular ET-tube followed by immediate extubation to CPAP (INSURE) or by thin catheter during spontaneous breathing and continued CPAP.

06

What researchers measure

Primary outcomes

  1. Oxygenation

    Arterial to alveolar ratio (a/A ratio)

    Time frame: 24 hours post-procedure

  2. Mechanical ventilation

    Need for intubation and mechanical ventilation (MV)

    Time frame: 48 hours post-procedure

Secondary outcomes

  1. Duration of ventilatory support

    Duration of MV (hours), CPAP (days), Oxygen (days)

    Time frame: Discharge

  2. Complications

    Incidence of air leaks, bronchopulmonary dysplasia, Systemic hypotension, retinopathy, necrotizing entercolitis, intraventricular hemorrhage, persistent duct

    Time frame: Discharge

  3. Mortality

    Death or composite outcome death/BPD

    Time frame: Discharge

  4. Length of stay

    Number of days in NICU and total in neonatal care, including home care

    Time frame: Discharge

Other outcomes

  1. Delay time

    Time from meeting the FiO2 or a/A ratio criteria for surfactant treatment until surfactant administration

    Time frame: 24 hours

  2. Intubation attempts

    Number of tries before successful intubation/placement of catheter

    Time frame: 24 hours

  3. PPV

    Positive pressure ventilation during the procedure - yes/no/duration (minutes)

    Time frame: 24 hours

  4. Stress and pain

    Changes in heart rate, blood pressure and BIIP-scales

    Time frame: 24 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2021 (actual). Primary completion is estimated for Dec 2025, 55 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2020
First posted
Jun 24, 2020
StartActual
May 21, 2021
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2026
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04445571
Responsible party
Kajsa Bohlin (MD, PhD, Karolinska Institutet) — Principal investigator
First posted
Jun 24, 2020
Start date
May 21, 2021
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 1, 2025

Study contacts

Kajsa Bohlin, MD
Contact
kajsa.bohlin@ki.se
+46858580000 ext. 81356
Mats Blennow, MD
Contact
mats.blennow@ki.se
+46858580000 ext. 81428

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion